Accordingly, pharmacological inhibition of the CBP/β-catenin complex blocks activation of primary mouse HSCs and enhances fibrosis resolution through the upregulation of matrix metalloproteinases (MMPs) expression in liver tissues from CCl4 mouse model of liver fibrosis [75]. Here, CREBBP is linked to Hepatic fibrosis.